<?xml version="1.0" encoding="UTF-8"?>
<table-wrap position="float" id="tbl3">
 <label>Table 3</label>
 <caption>
  <p>Agents that are currently being investigated or hypothetically considered for the treatment of SARS-CoV-2-infection.</p>
 </caption>
 <alt-text id="alttext0065">Table 3</alt-text>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th>Agent</th>
    <th>Chemical Formula</th>
    <th>Comments</th>
    <th>Clinical status</th>
    <th>References</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td align="left">Ribavirin (Antiviral)</td>
    <td align="left">(C
     <sub>8</sub>H
     <sub>12</sub>N
     <sub>4</sub>O
     <sub>5</sub>)
    </td>
    <td align="left">It is a guanosine analog used to treat the hepatitis C virus, respiratory syncytial virus (RSV), and some viral hemorrhagic fevers. 
     <italic>In vitro</italic> activity of ribavirin against SARS-CoV-2 (EC50 = 109.5 μM) was found to be less potent than remdesivir (EC50 = 0.77 μM) and chloroquine (EC50 = 1.13 μM).
    </td>
    <td align="left">ChiCTR2000029387,
     <break/>NCT04276688,
     <break/>NCT04293887, NCT04306497.
    </td>
    <td align="left">(
     <xref rid="bib146" ref-type="bibr">Wang et al., 2020</xref>, 
     <xref rid="bib147" ref-type="bibr">Wang et al., 2020b</xref>; 
     <xref rid="bib167" ref-type="bibr">Zumla et al., 2016</xref>)
    </td>
   </tr>
   <tr>
    <td align="left">Oseltamivir (Antiviral)</td>
    <td align="left">(C
     <sub>16</sub>H
     <sub>28</sub>N
     <sub>2</sub>O
     <sub>4</sub>)
    </td>
    <td align="left">Neuraminidase inhibitor used to treat influenza A and B. It blocks the release of viral particles from host cells, reducing the spread in the respiratory tract. Oseltamivir was already being used during the COVID-19 epidemic in China, and currently, it is in clinical trials.</td>
    <td align="left">NCT04255017,
     <break/>NCT04261270,
     <break/>NCT02735707.
    </td>
    <td align="left">
     <xref rid="bib141" ref-type="bibr">Uyeki (2018)</xref>
    </td>
   </tr>
   <tr>
    <td align="left">Nitazoxanide (Antiviral)</td>
    <td align="left">(C
     <sub>12</sub>H
     <sub>9</sub>N
     <sub>3</sub>O
     <sub>5</sub>S)
    </td>
    <td align="left">It is used to treat helminthic, protozoal, and viral infection-caused diarrhea. It inhibited SARS-CoV-2 
     <italic>in vitro</italic> with an EC50 of 2.12 μM in Vero E6 cells.
    </td>
    <td/>
    <td align="left">(
     <xref rid="bib50" ref-type="bibr">Guo, 2020</xref>; 
     <xref rid="bib146" ref-type="bibr">Wang et al., 2020</xref>, 
     <xref rid="bib147" ref-type="bibr">Wang et al., 2020b</xref>)
    </td>
   </tr>
   <tr>
    <td align="left">Darunavir
     <break/>{Antiretroviral and cobicistat (CYP3A inhibitor)}
    </td>
    <td align="left">(C
     <sub>27</sub>H
     <sub>37</sub>N
     <sub>3</sub>O
     <sub>7</sub>S)
     <break/>(C
     <sub>40</sub>H
     <sub>53</sub>N
     <sub>7</sub>O
     <sub>5</sub>S
     <sub>2</sub>)
    </td>
    <td align="left">Darunavir is an HIV protease inhibitor, whereas cobicistat boosts darunavir by inhibition of cytochrome P450 (CYP3A). In China, during February 2020, researchers announced that darunavir inhibited SARS-CoV-2 infection 
     <italic>in vitro</italic> and at a concentration of 300 μM inhibited viral replication 
     <italic>in vitro.</italic>
    </td>
    <td align="left">NCT04252274,
     <break/>NCT04304053,
     <break/>ChiCTR2000029541,
    </td>
    <td align="left">(
     <xref rid="bib91" ref-type="bibr">Mathias et al., 2010</xref>; 
     <xref rid="bib123" ref-type="bibr">Santos et al., 2019</xref>)
    </td>
   </tr>
   <tr>
    <td align="left">Azvudine (Antiviral)</td>
    <td align="left">(C
     <sub>9</sub>H
     <sub>11</sub>FN
     <sub>6</sub>O
     <sub>4</sub>)
    </td>
    <td align="left">It is a nucleoside reverse transcriptase inhibitor with activity on the HIV virus, hepatitis B virus, and hepatitis C virus. The clinical trials for Azvudine's efficacy against COVID-19 are going on in China.</td>
    <td align="left">ChiCTR2000030487, ChiCTR2000030424, ChiCTR2000029853.</td>
    <td align="left">
     <xref rid="bib144" ref-type="bibr">Wang et al. (2014)</xref>
    </td>
   </tr>
   <tr>
    <td align="left">Baloxavir marboxil (Antiviral)</td>
    <td align="left">(C
     <sub>27</sub>H
     <sub>23</sub>F
     <sub>2</sub>N
     <sub>3</sub>O
     <sub>7</sub>S)
    </td>
    <td align="left">Baloxavir marboxil (Xofluza) acidic endonuclease inhibitor used to treat Influenza A and B flu. The clinical trials for Xofluza's efficacy against COVID-19 are going on in China.</td>
    <td align="left">ChiCTR2000029544, ChiCTR2000029548.</td>
    <td align="left">
     <xref rid="bib110" ref-type="bibr">O'Hanlon and Shaw (2019)</xref>
    </td>
   </tr>
   <tr>
    <td align="left">Nelfinavir (Antiretroviral drug)</td>
    <td align="left">(C
     <sub>32</sub>H
     <sub>45</sub>N
     <sub>3</sub>O
     <sub>4</sub>S)
    </td>
    <td align="left">Based on homology modeling and molecular docking studies, nelfinavir is suggested to be a potential drug for SARS-CoV-2.</td>
    <td/>
    <td align="left">
     <xref rid="bib153" ref-type="bibr">Xu et al. (2020)</xref>
    </td>
   </tr>
   <tr>
    <td align="left">Ivermectin (Anti-parasitic)</td>
    <td align="left">(C
     <sub>48</sub>H
     <sub>74</sub>O
     <sub>14</sub>)
     <break/>22,23-dihydro-avermectin B
     <sub>1a</sub> (C
     <sub>47</sub>H
     <sub>72</sub>O
     <sub>14</sub>)
     <break/>22,23-dihydro-avermectin B
     <sub>1b</sub>
    </td>
    <td align="left">Ivermectin has shown to have antiviral activity against a broad range of viruses. Its antiviral activity is due to its ability to target the host importin (IMP) α/β1 nuclear transport proteins responsible for nuclear entry of cargoes such as integrase and NS5. A study by Caly et al. has demonstrated that ivermectin was able to inhibit SARS-CoV-2 
     <italic>in vitro</italic> with a single addition to Vero-hSLAM cells 2 h after infection with SARS-CoV-2. By 48h, there was a ~5000-fold decrease in viral RNA ivermectin treated samples as compared to control.
    </td>
    <td/>
    <td align="left">(
     <xref rid="bib11" ref-type="bibr">Caly et al., 2020</xref>; 
     <xref rid="bib156" ref-type="bibr">Yang et al., 2020</xref>)
    </td>
   </tr>
   <tr>
    <td align="left">Xiyanping (TCM)</td>
    <td/>
    <td align="left">Xiyanping is a Traditional Chinese Medicine (TCM) preparation with andrographolide as its main component and has antibacterial and antiviral properties. Xiyanping injection (100 mg, twice a day) is suggested for treating severe and critical COVID-19 patients in guidelines (7th edition) issued by the National Health Commission &amp; State Administration of Traditional Chinese Medicine.</td>
    <td align="left">ChiCTR2000030117,
     <break/>ChiCTR2000030218.
    </td>
    <td align="left">(
     <xref rid="bib26" ref-type="bibr">Commision, 2020</xref>; 
     <xref rid="bib137" ref-type="bibr">Tang, 2016</xref>)
    </td>
   </tr>
   <tr>
    <td align="left">ASC09 (HIV protease inhibitor)</td>
    <td align="left">(C
     <sub>38</sub>H
     <sub>53</sub>N
     <sub>5</sub>O
     <sub>7</sub>S
     <sub>2</sub>)
    </td>
    <td align="left">ASC-09 (TMC-310911) is a protease inhibitor (PI) that is which has demonstrated marked activity against a variety of HIV-1 strains. It is currently in clinical trials in combination with other drugs as a potential treatment for COVID-19.</td>
    <td align="left">ChiCTR2000029603, NCT04261270.</td>
    <td align="left">
     <xref rid="bib132" ref-type="bibr">Stellbrink et al. (2014)</xref>
    </td>
   </tr>
   <tr>
    <td align="left">Camostat mesylate</td>
    <td align="left">(C
     <sub>20</sub>H
     <sub>22</sub>N
     <sub>4</sub>O
     <sub>5</sub>)
     <break/>(CH
     <sub>3</sub>SO
     <sub>3</sub>H)
    </td>
    <td align="left">It is a transmembrane protease serine 2 (TMPRSS2) inhibitor approved in Japan to treat multiple conditions, including pancreatitis. In a study camostat mesylate was able to block SARS-CoV-2 infection of lung cells. It is currently in a clinical trial for the treatment of COVID-19.</td>
    <td align="left">NCT04321096.</td>
    <td align="left">
     <xref rid="bib55" ref-type="bibr">Hoffmann et al. (2020)</xref>
    </td>
   </tr>
   <tr>
    <td align="left">Vitamin C</td>
    <td align="left">(C
     <sub>6</sub>H
     <sub>8</sub>O
     <sub>6</sub>)
    </td>
    <td align="left">Vitamin C, also known as ascorbic acid, has antioxidant properties and acts as a cofactor for various enzymes. It is an electron donor, and electrons from ascorbate account for its physiological properties. However, there are no preclinical data of its activity against SARS-CoV-2. It has entered into clinical trials for the treatment of COVID-19.</td>
    <td align="left">NCT04264533,
     <break/>ChiCTR2000029768.
    </td>
    <td align="left">
     <xref rid="bib111" ref-type="bibr">Padayatty and Levine (2016)</xref>
    </td>
   </tr>
   <tr>
    <td align="left">Anakinra (Immunosuppressive)</td>
    <td align="left">(C
     <sub>759</sub>H
     <sub>1186</sub>N
     <sub>208</sub>O
     <sub>232</sub>S
     <sub>10</sub>)
    </td>
    <td align="left">It is an interleukin-1 receptor antagonist used to treat rheumatoid arthritis. Phase III clinical trial of anakinra in sepsis demonstrated reduced mortality in patients with hyper inflammation, without adverse effects. It is hypothesized that immunosuppression could improve the survival of COVID-19 patients.</td>
    <td align="left">NCT02735707,
     <break/>NCT04324021.
    </td>
    <td align="left">(
     <xref rid="bib97" ref-type="bibr">Mehta et al., 2020</xref>; 
     <xref rid="bib126" ref-type="bibr">Shakoory et al., 2016</xref>)
    </td>
   </tr>
   <tr>
    <td align="left">Losartan (Anti-hypertension)</td>
    <td align="left">(C
     <sub>22</sub>H
     <sub>23</sub>ClN
     <sub>6</sub>O)
    </td>
    <td align="left">Losartan is commonly used to treat high blood pressure and kidney disorders. It has been suggested that angiotensin II receptor 1 (ATR1) blockers like losartan can be used against SARS-CoV-2, which may reduce severity and mortality due to its infection. It is currently in clinical trials for the treatment of COVID-19.</td>
    <td align="left">NCT04335123,
     <break/>NCT04330300.
    </td>
    <td align="left">
     <xref rid="bib51" ref-type="bibr">Gurwitz (2020)</xref>
    </td>
   </tr>
   <tr>
    <td align="left">Emapalumab (Monoclonal antibody)</td>
    <td align="left">(C
     <sub>6430</sub>H
     <sub>9898</sub>N
     <sub>1718</sub>O
     <sub>2038</sub>S
     <sub>46</sub>)
    </td>
    <td align="left">It is an anti-interferon-gamma antibody used for the treatment of hemophagocytic lympho-histiocytosis (HLH). It has entered into a clinical trial along with anakinra for the treatment of COVID-19.</td>
    <td align="left">NCT04324021.</td>
    <td align="left">
     <xref rid="bib4" ref-type="bibr">Association (2018)</xref>
    </td>
   </tr>
   <tr>
    <td align="left">Bevacizumab (Monoclonal antibody)</td>
    <td align="left">(C
     <sub>6638</sub>H
     <sub>10160</sub>N
     <sub>1720</sub>O
     <sub>2108</sub>S
     <sub>44</sub>)
    </td>
    <td align="left">Bevacizumab is a humanized anti-vascular endothelial growth factor (VEGF) monoclonal antibody. It has entered into clinical trials for the treatment of COVID-19.</td>
    <td align="left">NCT04275414,
     <break/>NCT04305106.
    </td>
    <td align="left">
     <xref rid="bib143" ref-type="bibr">Wang et al. (2004)</xref>
    </td>
   </tr>
  </tbody>
 </table>
</table-wrap>
